AC
ACOG.US Alpha Cognition Inc
- Market cap
- USD 186M
- P/E
- -
- P/B
- 3.54x
- ROE
- -57.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ACOG.US undervalued?
Graham numberThe Graham number of Alpha Cognition Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alpha Cognition Inc fundamental analysis
No fundamental analysis for Alpha Cognition Inc yet.
Alpha Cognition Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation…
Full company profileAlpha Cognition Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alpha Cognition Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.2M | 19.3M |
| Gross Profit | - | - | - | - | - | - | -81.2K | 8.30M | 17.9M |
| Operating Income | -43.2K | -129K | -7.28M | -14.7M | -18.1M | -9.62M | -11.9M | -22.7M | -31.7M |
| EBITDA | -43.2K | -129K | -6.30M | -24.1M | -15.9M | -13.6M | -14.4M | -22.7M | -28.6M |
| Net Income | -43.2K | -119K | -7.39M | -24.9M | -16.3M | -13.8M | -14.6M | -20.7M | -30.5M |
| EPS | -0.91 | -3.60 | -3.56 | -12 | -5.99 | -3.84 | -2.02 | -1.17 | -1.40 |
| Balance Sheet | |||||||||
| Total Assets | - | - | 10.8M | 16.4M | 3.97M | 2.45M | 50.7M | 79.7M | 64.5M |
| Total Liabilities | - | - | 10.8M | 4.91M | 5.74M | 7.16M | 9.27M | 17.2M | 11.6M |
| Shareholders' Equity | - | - | 20.4K | 11.5M | -1.77M | -4.71M | 41.5M | 62.5M | 53.0M |
| Cash & Short-term Investments | - | - | 7.57M | 14.4M | 2.80M | 1.49M | 48.5M | 66.1M | 41.4M |
| Total Debt | - | - | 4.11M | 1.37M | 1.63M | 1.22M | 911K | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | - | -47.4K | -6.94M | -12.6M | -12.4M | -8.73M | -7.76M | -20.4M | -37.3M |
| Capital Expenditure | - | 0.00 | 11.8K | 81.1K | 6.55K | 5.00 | 26.7K | 293K | 200K |
| Free Cash Flow | - | -47.4K | -6.96M | -12.7M | -12.4M | -8.73M | -7.78M | -20.7M | -37.5M |
| Ratios | |||||||||
| ROE | - | - | -36,133.7% | -216.5% | - | - | -35.3% | -33.1% | -57.7% |
| ROA | - | - | -68.6% | -151.7% | -410.5% | -561.6% | -28.8% | -25.9% | -47.3% |
| Net Profit Margin | - | - | - | - | - | - | - | -202.2% | -158.6% |
| Debt to Equity | - | - | 200.84x | 0.12x | - | - | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alpha Cognition Inc dividends
Alpha Cognition Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:25 on Nov 5, 2024.
Who owns Alpha Cognition Inc
- Insiders 5.13%
- Institutions 60.03%
- Public & others 34.83%
- Shares outstanding 21.8M
- Free float 11.0M
Top funds holding ACOG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| 1290 Essex Small Cap Growth I | 109K | 0.50% | +0.53% | Sep 2026 |
| Mandarine Global Microcap G EUR | 17.0K | 0.08% | 0.00% | Jul 2026 |
| Fidelity Nasdaq Composite Index | 14.3K | 0.07% | 0.00% | Aug 2026 |
| Avantis US Small Cap Equity ETF | 12.2K | 0.06% | +1.06% | Oct 2026 |
| Dimensional Global Core Equity USD Acc | 4.53K | 0.02% | +56.30% | Sep 2026 |
| DFA US Core Equity Class F | 4.18K | 0.02% | 0.00% | Aug 2026 |
| Dimensional World Equity GBP Acc | 2.87K | 0.01% | +137.65% | Sep 2026 |
| Dimensional International Core Eq Acc | 2.48K | 0.01% | 0.00% | Sep 2026 |
| DFA US Vector Equity Class F | 1.80K | 0.01% | 0.00% | Aug 2026 |
| Dimensional World Allc 60/40 GBP Acc | 1.74K | 0.01% | 0.00% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 1.72K | 0.01% | -0.41% | Sep 2026 |
Top institutions holding ACOG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Opaleye Management Inc | 2.90M | 13.30% | +13.02% | Jun 2026 |
| Solas Capital Management LLC | 1.92M | 8.84% | 0.00% | Jun 2026 |
| Awm Investment Company Inc | 1.67M | 7.68% | 0.00% | Jun 2026 |
| Cable Car Capital LLC | 1.38M | 6.35% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 836K | 3.84% | -20.83% | Jun 2026 |
| Sphera Funds Management Ltd. | 546K | 2.51% | -3.84% | Jun 2026 |
| Alyeska Investment Group, L.P. | 365K | 1.68% | 0.00% | Jun 2026 |
| Aristides Capital LLC | 219K | 1.00% | 0.00% | Jun 2026 |
| CANTOR FITZGERALD, L. P. | 218K | 1.00% | +15.48% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 189K | 0.87% | -26.23% | Jun 2026 |
| Citadel Advisors Llc | 97.5K | 0.45% | +8.88% | Jun 2026 |
| Villere St Denis J & Co Llc | 71.2K | 0.33% | 0.00% | Jun 2026 |
| Tudor Investment Corp Et AL | 61.6K | 0.28% | 0.00% | Jun 2026 |
| ACT Capital Management, LLC | 51.5K | 0.24% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 23.7K | 0.11% | 0.00% | Sep 2026 |
| Berkshire Asset Management Inc | 19.8K | 0.09% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 18.8K | 0.09% | +18.54% | Jun 2026 |
| Geode Capital Management, LLC | 12.0K | 0.06% | 0.00% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 5.29K | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 1.46K | 0.01% | +232.42% | Jun 2026 |
Alpha Cognition Inc company profile
- Company name
- Alpha Cognition Inc
- Ticker
- ACOG.US
- ISIN
- CA02074J5017
- Exchange
- USA Stocks
- Listed since
- Nov 12, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Fiscal year end
- December
- Address
- 1452 Hughes Street, Grapevine, TX, United States, 76051
- Phone
- 858 344 4375
- Website
- alphacognition.com
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Alpha Cognition Inc management
7- Mr. Michael E. McFadden B.B.A.CEO & Director · born 1967
- Mr. Kenneth Anthony Cawkell B.A., LL.B.Founder, Consultant, Corporate Secretary & Director · born 1951
- Mr. Henry H. Du CPAVP of Finance & Accounting and Interim CFO · born 1979
- Ms. Lauren D'Angelo M.B.A.Chief Operating Officer · born 1978
- Dr. Denis G. Kay M.Sc., Ph.D.Chief Scientific Officer · born 1957
- Mr. Timothy AyersHead of Compliance
- Ms. Christine RevealVice President of Marketing & Commercial Strategy